The deadly business of an unregulated global stem cell industry (original) (raw)
2017, Journal of medical ethics
https://doi.org/10.1136/MEDETHICS-2016-104046
Sign up for access to the world's latest research
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Abstract
In 2016, the Office of the State Coroner of New South Wales released its report into the death of an Australian woman, Sheila Drysdale, who had died from complications of an autologous stem cell procedure at a Sydney clinic. In this report, we argue that Mrs Drysdale's death was avoidable, and it was the result of a pernicious global problem of an industry exploiting regulatory systems to sell unproven and unjustified interventions with stem cells.
Related papers
Banking on it: Public policy and the ethics of stem cell research and development
If the therapeutic potential of stem cell-based therapies is ever realized, demand for stem cells and derivative tissues will be tremendous and will create new challenges for health care systems, especially publicly funded health care systems. We propose a framework for the ethical analysis of stem cell research and development that considers the welfare of communities, tissue recipients, and cell sources in relation to a range of stem cell production and distribution options. Ethical desiderata include: equitable access, maximized potential therapeutic benefit across demographic and disease groups, and reasonable cost. Other ethical priorities include the minimization of stem cell line and tissue wastage, risk of immune rejection, risk of transmitting diseases, the use of human embryos, and risk to those contributing source cells. We array plausible sources of stem cells and distribution strategies to characterize 12 potential models for producing and distributing cells and tissues in the future. We describe ''personalized'', ''matched'', and ''universalized'' models, and compare the ethical acceptability of these models. Popular and scientific discourses about stem cells typically emphasize personalized or matched stem cell distribution models. We show that universalized models may ultimately best serve the interest of taxpayers, communities and patients who hold high stakes in the therapeutic success of stem cell science. They are therefore highly worthy of scientific pursuit. This conclusion is provisional and the framework must be reapplied as scientific knowledge, technological capacity and ethical mores evolve.
GOING TO THE ROOTS OF THE STEM CELL CONTROVERSY
The purpose of this paper is to describe the scientific background to the current ethical and legislative debates about the generation and use of human stem cells, and to give an overview of the ethical issues underlying these debates.
BMC Medical Ethics
Background: The marketing of unproven direct-to-consumer stem cell interventions is becoming widespread in Canada. There is little evidence supporting their use and they have been associated with a range of harms. Canada has been slower to act against clinics offering these interventions than other jurisdictions, including the United States. Here, we outline the regulatory and policy tools available in Canada to address this growing problem. Main body: Health Canada's regulations governing cell therapies are complex, but recent statements make it clear that Health Canada believes it has jurisdiction over many of the currently marketed stem cell interventions. Still, further regulatory clarity is needed from Health Canada, as are increased directed enforcement efforts on interventions that fall within their scope. The Competition Bureau, via the Competition Act, prohibits advertisers from making materially false or misleading promotional representations. The Competition Bureau could collaborate with the scientific community to analyze the claims of existing clinics in Canada, and impose sanctions upon those who breach the established standard. Professional regulators, including provincial colleges of physicians and surgeons, have considerable power over what products and services their members can offer. Every college of physicians in Canada requires, via policy and codes of ethics, that doctors maintain evidence-based practices. This requirement is incompatible with offering many unproven stem cell interventions. Litigation may be another tool, including the use of fraud, misrepresentation and/or negligence claims for failing to meet the required standard of care. Finally, political pressure on federal and provincial lawmakers could encourage changes to marketing, cell therapy and professional regulations that would allow a more comprehensive response. Conclusions: In sum, there are many existing tools that can be used to protect the public from unproven stem cell interventions. Increased bureaucratic will and grassroots efforts are needed in order to effect a positive policy response.
A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore
Cytotherapy, 2018
We report on a roundtable event hosted in Singapore that sought to identify some of the ethical and regulatory challenges in translating autologous cell-based interventions, particularly those claiming to involve stem cells, into safe and effective therapies and to propose some solutions to encourage responsible innovation with these products. Challenges are identified in the three areas of cell manufacturing and processing, innovative uses of autologous cells in clinical practice and standards of evidence. Proposed solutions are discussed within a cooperative model of statutory laws and regulations that can enable product development with autologous cells and professional codes and standards that can encourage ethical conduct in clinical practice. Future research should be directed toward establishing regional networks for the development of internationally consistent standards in manufacturing and ethical codes of conduct for innovating with stem cells, and other autologous cells, and fostering ongoing exchange between jurisdictions.
Renewing regulatory practices: the case of stem cells
International Journal of Healthcare Technology and Management, 2007
This paper examines the political decisions made by three countries-Denmark, the Netherlands, and Germany-about stem cell research. It recommends directing the regulatory practices away from today's practice, based on regulation of technological frameworks, and towards a regulatory policy based on technological road-mapping. Regulatory practices would thus be based on the content of the technologies in question, and on the vision they seem to show. Its conclusion suggests a positive side-effect of such a shift in the regulatory paradigm: that technological road-mapping can be used as a communication tool to deal with priorities in the healthcare system when technologies are at an embryonic stage.
Regulation of Human Stem Cell Research in Australia
Stem Cell Reviews and Reports, 2009
Australia is currently well placed to contribute to the global growth of human stem cell research. However, as the science has progressed, authorities have had to deal with the ongoing challenges of regulating such a fast moving field of scientific endeavour. Australia’s past and current approach to regulating the use of embryos in human embryonic stem cell research provides an insight into how Australia may continue to adapt to future regulatory challenges presented by human stem cell research. In the broader context, a number of issues have been identified that may impact upon the success of future human stem cell research in Australia.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.
References (23)
- Coroners Court New South Wales. Inquest into the death of Sheila Drysdale. 2016 (10 August 2016). http://www.coroners.justice.nsw.gov.au/Documents/Findings% 20Drysdale.pdf
- Food and Drug Administration. What are the Risks or Complications? 2015 (22 August 2016). http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ SurgeryandLifeSupport/Liposuction/ucm256139.htm
- Wyles CC, Houdek MT, Behfar A, et al. Mesenchymal stem cell therapy for osteoarthritis: current perspectives. Stem Cells Cloning 2015;8:117-24.
- Tong LM, Fong H, Huang Y. Stem cell therapy for Alzheimer's disease and related disorders: current status and future perspectives. Exp Mol Med 2015;47:e151.
- Amemori T, Jendelova P, Ruzicka J, et al. Alzheimer's disease: mechanism and approach to cell therapy. Int J Mol Sci 2015;16:25961.
- O'Neill O. Some limits of informed consent. J Med Ethics 2003;29:4-7.
- hba legal. White v Johnston [2015] NSWCA 18 2015 (22 August 2016). http:// hbalegal.com/wp-content/uploads/2015/06/White-v-Johnston-2015-NSWCA-18.pdf
- Tuffs A. Stem cell treatment in Germany is under scrutiny after child's death. BMJ 2010;341:c6203.
- Pepper J. Croydon man died in long haul op, inquest hears: Croydon Guardian. 2012 (28 August 2016). http://www.croydonguardian.co.uk/news/9491936\. Paraplegic_man_died_in_long_haul_op__inquest_hears/
- Cyranoski D. Korean deaths spark inquiry. Nature 2010;468:485.
- Freeman L. Bonita Springs stem cell doctor Grekos loses two more rounds in court. Naples Daily News 2014 (3 November 2016). http://archive.naplesnews.com/news/ local/bonita-springs-stem-cell-doctor-grekos-loses-two-more-rounds-in-court-ep- 589350147-337085341.html
- Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to- consumer industry. Cell Stem Cell 2016;19:154-7.
- Fujita M, Hatta T, Ozeki R, et al. The current status of clinics providing private practice cell therapy in Japan. Regen Med 2016;11:23-32.
- McLean AK, Stewart C, Kerridge I. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure? J Law Med 2014;22:65-89.
- Regenberg AC, Hutchinson LA, Schanker B, et al. Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells 2009;27: 2312-19.
- Lau D, Ogbogu U, Taylor B, et al. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 2008;3:591-4.
- Berger I, Ahmad A, Bansal A, et al. Global distribution of businesses marketing stem cell-based interventions. Cell Stem Cell 2016;19:158-62.
- Sleeboom-Faulkner M, Patra PK. Experimental stem cell therapy: Biohierarchies and bionetworking in Japan and India. Soc Stud Sci 2011;41:645-66.
- Lysaght T, Kerridge I, Sipp D, et al. Ethical and regulatory challenges with autologous adult stem cells: a comparative review of international regulations. J Bioeth Inq doi: 10.1007/s11673-017-9776-y. [Epub ahead of print 28 Feb 2017].
- 20 Petersen A, Seear K, Munsie M. Therapeutic journeys: the hopeful travails of stem cell tourists. Sociol Health Illn. 2014;36:670-85.
- Ogbogu U, Rachul C, Caulfield T. Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better? Regen Med 2013;8:361-9.
- Gottweis H, Salter B, Waldby C. The global politics of human embryonic stem cell science: regenerative medicine in transition. Basingstoke: Palgrave, 2009.
- Owen R, Macnaghten P, Stilgoe J. Responsible research and innovation: from science in society to science for society, with society. Sci Publ Policy 2012;39:751-60.
Related papers
Stem Cell Research & Therapy, 2015
An increasing number of private clinics in Australia are marketing and providing autologous stem cell therapies to patients. Although advocates point to the importance of medical innovation and the primacy of patient choice, these arguments are unconvincing. First, it is a stark truth that these clinics are flourishing while the efficacy and safety of autologous stem cell therapies, outside of established indications for hematopioetic stem cell transplantation, are yet to be shown. Second, few of these therapies are offered within clinical trials. Third, patients with chronic and debilitating illnesses, who are often the ones who take up these therapies, incur significant financial burdens in the expectation of benefiting from these treatments. Finally, the provision of these stem cell therapies does not follow the established pathways for legitimate medical advancement. We argue that greater regulatory oversight and professional action are necessary to protect vulnerable patients and that at this time the provision of unproven stem cell therapies outside of clinical trials is unethical.
The promise of stem cells and the prospect of curing disease, for which no therapy currently exists, continue to drive global interest. However, several misconceptions persist in general society and, to an extent, among the medical fraternity. These misconceptions, coupled with irresponsible clinical practices, have resulted in a multitude of controversies, all of which are to the detriment of vulnerable patients. Stem cell tourism is an international industry that has been on the rise in recent years, and thousands of families have been enticed into paying for unproven stem cell therapies. Guidelines and legislation in this regard are presently being developed and implemented globally with the aim of providing ethically sound reference material for patients, practitioners and regulators. Although governments and policy makers worldwide are actively trying to protect patients by regulating the sources, research and uses of stem cells in humans, the existing rules and regulations have been the source of much controversy and sometimes function in contradiction. Regulatory environments also differ significantly between countries, which need global scientific cooperation for sound and safe translation of stem cell therapies. This also makes global regulatory cohesion very difficult. Without legal and regulatory certainty regarding stem cell research and the translation thereof, scientists risk their research integrity and liability, while patients might suffer harm and exploitation. This chapter aims to provide an overview of the current global regulatory framework and the ethical contexts in which it is embedded, as well as anticipated legal developments and recommendations. Chapter objectives The primary objective is to describe the scope of currently accepted stem cell therapies and to align this with the expectations of society. International guidelines and legislature play a critical role in striking a balance between the current status of stem cell research and the hope of society, while also limiting the extent of
Ethics of International Stem Cell Treatments and the Risk-Benefit of Helping Patients
Biochemistry, 2023
Numerous and diverse participants are involved in the development of novel therapies: patients, physicians, scientists, sponsors, governing bodies, lawmakers, institutional review boards, and bioethics proponents. While the welfare of the patient must always and unquestionably be at the forefront of any intervention along with informed consent, their wishes, their requests, and their expectations should also be considered at every step. The availability of stem cell research in various countries with dissimilar regulatory agencies has opened the door for thought-provoking questions about their validity from an ethical, legal, and moral perspective, which will be addressed in this chapter, framed within the doctor-patient relationship.
Stem Cell Policy Exceptionalism: Proceed with Caution
Stem Cell Reviews and Reports, 2012
The term "stem cell exceptionalism" has been used to characterize the policy response to controversies surrounding human embryonic stem cell research. For example, governments and funding agencies have adopted policies governing the derivation and use of human embryonic stem cell lines. These policies have effectively served to fill gaps in existing guidelines and regulations and signal that scientists are committed to a responsible framework for the conduct of research involving human embryos. Recent publications discuss whether ethical and policy issues associated with induced pluripotent cells (iPSCs) from non-embryonic sources create a need for further policy intervention. We suggest many of the issues identified by commentators may be addressed through the application of established policy frameworks governing the use of tissue, human stem cells, and research participation by human research subjects. To the extent, iPSC research intersects with hESC research (e.g. the creation of human gametes and/or embryos), the policy framework governing hESC appears sufficiently robust at this time.
The Stem Cell Research Environment: A Patchwork of Patchworks
Stem Cell Reviews and Reports, 2009
Few areas of recent research have received as much focus or generated as much excitement and debate as stem cell research. Hope for the therapeutic promise of this field has been matched by social concern associated largely with the sources of stem cells and their uses. This interplay between promise and controversy has contributed to the enormous variation that exists among the environments in which stem cell research is conducted throughout the world. This variation is layered upon intra-jurisdictional policies that are also often complex and in flux, resulting in what we term a 'patchwork of patchworks'. This patchwork of patchworks and its implications will become increasingly Stem Cell Rev and Rep (2009) 5:82-88
Dangerous Science: Online Promotion of Unproven Stem Cell Therapies and Global Health Risks
Journal of Commercial Biotechnology, 2013
Stem cell-based therapies represent a potential pathway for a new era of 21st century regenerative medicine. In support of this new form of treatment, a global multibillion-dollar research endeavor is currently underway in an effort to establish a scientific evidence base for safe and effective clinical use of stem cells. At present, due to its early stages, only a few stem cell therapies are approved for use. Yet despite very limited evidence-based data, a proliferation of questionable and often illegal stem cell providers around the world are now offering unfettered access to largely experimental stem cell treatment claiming cures for virtually any disease or condition. These stem cell clinics promote their services globally to patients using unregulated Internet and forms of direct-to-consumer advertising. In this paper we examine marketing characteristics of these questionable stem cell clinics and discuss pathways of access through the globalization of medical tourism. We conclude with an examination of the similarities between unproven stem cell therapy access and illicit online pharmacies and explore possible lessons that can be learned to inform future global regulation and policymaking in this arena.
Hofstra L. …, 2008
Every progress in science in the last decades, from the moment it was absorbed into technology and thus introduced into the factual world where we live our everyday lives, has brought with it a veritable avalanche of fabulous instruments and ever more ingenious machinery. All of this makes it more unlikely every day that man will encounter anything in the world around him that is not man-made and hence is not, in the last analysis, he himself in a different disguise.
Related topics
Cited by
Characterisation and In Vivo Safety of Canine Adipose-Derived Stem Cells
Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
The study characterises canine adipose-derived stem cells (cASCs) in comparison to human ASCs (hASCs) and tests their safety in a canine model after intravenous administration. cASCs from two dogs were cultured under hypoxic conditions in a medium supplemented with autologous serum. They were plastic adherent, spindle-shaped cells that expressed CD73, CD90, and CD44 but lacked CD45, CD14, HLA-DR, and CD34. cASCs differentiated toward adipogenic, osteogenic, and chondrogenic lineages, although adipogenic differentiation capacity was low. Blast transformation reaction demonstrated that these cells significantly suppress T-cell proliferation, and this ability is dose-dependent. Intravenous administration of a cell freezing medium, therapeutic dose of cASCs (2 × 106 live cells/kg), and five times higher dose of cASCs showed no significant side effects in two dogs. Microscopic tissue lesions were limited to only mild, non-specific changes. There were no signs of malignancy. The results o...
Stem Cell Research & Therapy
Background Mesenchymal stem or stromal cells are the most widely used cell therapy to date. They are heterogeneous, with variations in growth potential, differentiation capacity and protein expression profile depending on tissue source and production process. Nomenclature and defining characteristics have been debated for almost 20 years, yet the generic term ‘MSC’ is used to cover a wide range of cellular phenotypes. Against a documented lack of definition of cellular populations used in clinical trials, our study evaluated the extent of characterisation of the cellular population or study drug. Methods A literature search of clinical trials involving mesenchymal stem/stromal cells was refined to 84 papers upon application of pre-defined inclusion/exclusion criteria. Data were extracted covering background trial information including location, phase, indication, tissue source and details of clinical cell population characterisation (expression of surface markers, viability, differe...
Regenerative Medicine
The prevalence of businesses selling autologous stem cell-based interventions to patients in Australia has raised serious concerns about how weaknesses in regulation have enabled the emergence of an industry that engages in aggressive marketing of unproven treatments to patients. Little is known about how patients experience this marketing and their subsequent interactions with practitioners. This paper reports results from 15 semistructured interviews with patients and carers, and also draws upon discussion conducted with patients, carers and family members (22 participants) in a workshop setting. We explore how Australian patients and carers understand and experience these interventions, and how their presumptions about the ethics of medical practice, and the regulatory environment in Australia have conditioned their preparedness to undergo unproven treatments.
Regenerative medicine, 2017
This article examines online marketing practices of Japanese and Australian clinics offering putative autologous stem cell treatments. We conducted google searches for keywords related to stem cell therapy and stem cell clinics in English and Japanese. We identified websites promoting 88 point-of-sale clinics in Japan and 70 in Australia. Our findings provide further evidence of the rapid global growth in clinics offering unproven stem cell interventions. We also show that these clinics adopt strategies to promote their services as though they are consistent with evidentiary and ethical standards of science, research and medicine. Unless addressed, these practices risk harming not only vulnerable patients but also undermining public trust in science and medicine.